"In Are Your Meds making You Sick? author Robert S. Gold, RPh, MBA, a clinical hospital pharmacist and affiliate instructor of clinical pharmacy at Purdue University with over 27 years of experience, shows the reader how to think like a clinical hospital pharmacist. He lists his 16 Rules of Safe Medication Use that, if followed, can help prevent the common problems that medications can cause; gives specific examples and scenarios featuring the thirty-six drugs that are the most common offenders; and explains how even seemingly good drugs can harm a patient's kidney, liver, brain and heart if the patient's medical history and physical vulnerabilities are not taken into account"--
Robert S. Gold, RPh, MBA, a clinical hospital pharmacist and affiliate instructor of clinical pharmacy at Purdue University with over 27 years of experience, shows the reader how to think like a clinical hospital pharmacist. He lists his 16 Rules of Safe Medication Use that, if followed, can help prevent the common problems that medications can cause; gives specific examples and scenarios featuring the thirty-six drugs that are the most common offenders; and explains how even seemingly good drugs can harm a patient's kidney, liver, brain and heart if the patient's medical history and physical vulnerabilities are not taken into account. Are Your Meds Making You Sick? A Pharmacist's Guide to Avoiding Dangerous Drug Interactions, Reactions and Side-Effects is highly accessible and formatted for quick reference by any layperson.
Understanding risk -- Putting risk in perspective -- Risk charts : a way to get perspective -- Judging the benefit of a health intervention -- Not all benefits are equal : understand the outcome -- Consider the downsides -- Do the benefits outweight the downsides? -- Beware of exaggerated importance -- Beware of exaggerated certainty -- Who's behind the numbers?
When a mother discovers that the drugs her daughter has been prescribed are making her physically and mentally ill, she tries to have the group home decrease them in stages and find herself fighting against an invincible system. That system includes the regulatory organizations, the funding organizations and of course the pharmaceutical companies who make the drugs. However the drug manufacturers do not recommend the mixing of drugs which is being practiced in 24/7 group homes, and which is a requirement for food and shelter there.
A NEW YORK TIMES BESTSELLER * New York Times Notable Book * Best Book of the Year: New York Public Library, Kirkus Reviews, Science Friday With a new postscript by the author From an award-winning journalist, an explosive narrative investigation of the generic drug boom that reveals fraud and life-threatening dangers on a global scale—The Jungle for pharmaceuticals Many have hailed the widespread use of generic drugs as one of the most important public-health developments of the twenty-first century. Today, almost 90 percent of our pharmaceutical market is comprised of generics, the majority of which are manufactured overseas. We have been reassured by our doctors, our pharmacists and our regulators that generic drugs are identical to their brand-name counterparts, just less expensive. But is this really true? Katherine Eban’s Bottle of Lies exposes the deceit behind generic-drug manufacturing—and the attendant risks for global health. Drawing on exclusive accounts from whistleblowers and regulators, as well as thousands of pages of confidential FDA documents, Eban reveals an industry where fraud is rampant, companies routinely falsify data, and executives circumvent almost every principle of safe manufacturing to minimize cost and maximize profit, confident in their ability to fool inspectors. Meanwhile, patients unwittingly consume medicine with unpredictable and dangerous effects. The story of generic drugs is truly global. It connects middle America to China, India, sub-Saharan Africa and Brazil, and represents the ultimate litmus test of globalization: what are the risks of moving drug manufacturing offshore, and are they worth the savings? A decade-long investigation with international sweep, high-stakes brinkmanship and big money at its core, Bottle of Lies reveals how the world’s greatest public-health innovation has become one of its most astonishing swindles.
This second edition volume is a desktop reference guide on nutrition and its clinical implications for health and disease. Presented in a new softcover format and user-friendly style, it serves as a valuable resource of practical information on nutrition for physicians and other healthcare professionals in their daily practice. The book covers all important aspects of nutrition including basic nutritional principles, nutrition through the lifecycle and optimal nutrition patterns through all stages of development, and diet and its role in prevention, cause, and treatment of disease. Nutrition Guide for Physicians and Related Healthcare Professionals is thoroughly updated from its predecessor, Nutrition Guide for Physicians and provides a wide perspective of the impact that nutrition has upon medical practice and will be an indispensable resource for primary care physicians and other medical professionals.
This best-selling resource has a worldwide reputation as the leader in its field. Focusing on human immunology and biology, while also reporting on scientific experimentation and advancement, it provides comprehensive coverage of state-of-the-art basic science as well as authoritative guidance on the practical aspects of day-to-day diagnosis and management. This new edition includes 700 full-color illustrations and a new, more accessible format to make finding information a snap for the busy practitioner. And this Expert Consult Edition offers online access to the complete contents of the 2-volume set, fully searchable, and much more. Includes a glossary of allergy and immunology for quick and easy reference. Contains keypoints and clinical pearls highlighted to find important information quickly. links to useful online resources both for you and for your patients. Offers contributions from hundreds of international authorities for world-class expertise in overcoming any clinical challenge.
An exposé on Big Pharma and the American healthcare system’s zeal for excessive medical testing, from a nationally recognized expert More screening doesn’t lead to better health—but can turn healthy people into patients. Going against the conventional wisdom reinforced by the medical establishment and Big Pharma that more screening is the best preventative medicine, Dr. Gilbert Welch builds a compelling counterargument that what we need are fewer, not more, diagnoses. Documenting the excesses of American medical practice that labels far too many of us as sick, Welch examines the social, ethical, and economic ramifications of a health-care system that unnecessarily diagnoses and treats patients, most of whom will not benefit from treatment, might be harmed by it, and would arguably be better off without screening. Drawing on 25 years of medical practice and research on the effects of medical testing, Welch explains in a straightforward, jargon-free style how the cutoffs for treating a person with “abnormal” test results have been drastically lowered just when technological advances have allowed us to see more and more “abnormalities,” many of which will pose fewer health complications than the procedures that ostensibly cure them. Citing studies that show that 10% of 2,000 healthy people were found to have had silent strokes, and that well over half of men over age sixty have traces of prostate cancer but no impairment, Welch reveals overdiagnosis to be rampant for numerous conditions and diseases, including diabetes, high cholesterol, osteoporosis, gallstones, abdominal aortic aneuryisms, blood clots, as well as skin, prostate, breast, and lung cancers. With genetic and prenatal screening now common, patients are being diagnosed not with disease but with “pre-disease” or for being at “high risk” of developing disease. Revealing the economic and medical forces that contribute to overdiagnosis, Welch makes a reasoned call for change that would save us from countless unneeded surgeries, excessive worry, and exorbitant costs, all while maintaining a balanced view of both the potential benefits and harms of diagnosis. Drawing on data, clinical studies, and anecdotes from his own practice, Welch builds a solid, accessible case against the belief that more screening always improves health care.
M. WILKINSON Patients with frequent or daily headaches pose a very difficult problem for the physician who has to treat them, particularly as many patients think that there should be a medicine or medicines which give them instant relief. In the search for the compound which would meet this very natural desire, many drugs have been manufactured and the temptation for the physician is either to increase the dose of a drug which seems to be, at any rate, partially effective, or to add one or more drugs to those which the patient is already taking. Although there have been some references to the dangers of overdosage of drugs for migraine in the past, it was not until relatively recently that it was recognized that drugs given for the relief of headache, if taken injudiciously, may themselves cause headache. The first drugs to be implicated in this way were ergotamine and phenazone. In the case of ergotamine tartrate, the dangers of ergotism were well known as this was a disorder which had been known and written about for many years. In the treatment of headache, fully blown ergotism is rare and in recent years has usually been due to self-medication in doses much greater than those prescribed although there are a few recorded cases where toxic amounts have been given.
Among the many who serve in the United States Armed Forces and who are deployed to distant locations around the world, myriad health threats are encountered. In addition to those associated with the disruption of their home life and potential for combat, they may face distinctive disease threats that are specific to the locations to which they are deployed. U.S. forces have been deployed many times over the years to areas in which malaria is endemic, including in parts of Afghanistan and Iraq. Department of Defense (DoD) policy requires that antimalarial drugs be issued and regimens adhered to for deployments to malaria-endemic areas. Policies directing which should be used as first and as second-line agents have evolved over time based on new data regarding adverse events or precautions for specific underlying health conditions, areas of deployment, and other operational factors At the request of the Veterans Administration, Assessment of Long-Term Health Effects of Antimalarial Drugs When Used for Prophylaxis assesses the scientific evidence regarding the potential for long-term health effects resulting from the use of antimalarial drugs that were approved by FDA or used by U.S. service members for malaria prophylaxis, with a focus on mefloquine, tafenoquine, and other antimalarial drugs that have been used by DoD in the past 25 years. This report offers conclusions based on available evidence regarding associations of persistent or latent adverse events.
